Orlin Sergev
Endocrinology, Diabetes & Metabolism · Summerville, SCNPI 1003845207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,138 of the $29,376 with a category attached, or 65.1%. 54 manufacturers reported payments, led by Bayer at 45.4% of the total. Reporting peaked in 2022 at $9,099 and has fallen 73.1% since, to $2,444 in 2025.
Across 515 payments — averaging $57.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$13K
- Tandem Diabetes Care, Inc.$7K
- AbbVie$907
- Medtronic$871
- Sanofi-aventis U.S. LLC$720
- Lilly USA, LLC$633
- plus $6K from 48 others
What the payments were for
- Speaking & faculty fees$19,13865%
- Food & beverage$10,07634%
- Education$1030%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$12,288
- t-slim insulin pump$4,200
- t:slim X2 insulin pump$2,650
- MINIMED 780G$381
- Tymlos$117
How this compares
$29,376 in reported general payments places this provider in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 183 | $291,067 |
| OzempicSemaglutide | 158 | $204,964 |
| TrulicityDulaglutide | 78 | $125,806 |
| KerendiaFinerenone | 69 | $83,739 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $83,572 |
| JardianceEmpagliflozin | 56 | $76,024 |
| FarxigaDapagliflozin Propanediol | 62 | $61,149 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $33,111 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $31,868 |
| JanuviaSitagliptin Phosphate | 34 | $31,380 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 113 | $21,688 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $21,226 |
| SynthroidLevothyroxine Sodium | 184 | $19,451 |
| TradjentaLinagliptin | 17 | $18,792 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $18,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $633 | $425,751290 claims |
| Novo NordiskOzempic, Novolog | $342 | $216,916192 claims |
| Boehringer IngelheimJardiance, Tradjenta | $39 | $94,81573 claims |
| BayerKerendia | $13,346 | $83,73969 claims |
| AstraZenecaFarxiga | $93 | $61,14962 claims |
| MerckJanuvia, Janumet | $25 | $52,60651 claims |
| AbbVieSynthroid | $907 | $19,451184 claims |
| IBSA Pharma Inc.Tirosint | $620 | $5,96815 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $266 | $5,408198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Summerville
- Joseph MathewsSummerville$168K
- John SchenckSummerville$12K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
- Beatrice HullCharleston$214K
- Brittany HendersonMount Pleasant$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.